Semaglutide is a GLP-1 receptor agonist medicine that mimics a natural gut hormone involved in appetite and blood sugar regulation. In Australia it is sold under the brand names Ozempic, registered for type 2 diabetes, and Wegovy, registered for weight management in eligible patients.
Semaglutide is available only on prescription. Suitability depends on medical history, other health conditions and treatment goals, all of which a doctor reviews during consultation. Supply availability in Australia has varied, so prescribers also consider current stock when planning care.